Weiss Elliot T, Chapas Anne, Brightman Lori, Hunzeker Christopher, Hale Elizabeth K, Karen Julie K, Bernstein Leonard, Geronemus Roy G
Laser & Skin Surgery Center of New York, 317 E 34th St, New York, NY 10016, USA.
Arch Dermatol. 2010 Feb;146(2):133-40. doi: 10.1001/archdermatol.2009.358.
To assess the safety and efficacy of ablative fractional resurfacing (AFR) for nonacne atrophic scarring.
In this before-and-after trial, each scar received 3 AFR treatments and 6 months of follow-up.
Private academic practice.
Fifteen women with Fitzpatrick skin types I to IV, aged 21 to 66 years, presented with 22 nonacne atrophic scars between June 1 and November 30, 2007. Three patients (3 scars) were excluded from the study after receiving 1 AFR treatment and not returning for follow-up visits. The remaining 12 patients (19 scars) completed all 3 treatments and 6 months of follow-up.
Each scar received 3 AFR treatments at 1- to 4-month intervals.
Erythema, edema, petechiae, scarring, crusting, and dyschromia were graded after treatment and through 6 months of follow-up. Skin texture, pigmentation, atrophy, and overall appearance were evaluated after treatment and through 6 months of follow-up by the patient and a nonblinded investigator. A 3-dimensional optical profiling system generated high-resolution topographic representations of atrophic scars for objective measurement of changes in scar volume and depth.
Adverse effects of treatment were mild to moderate, and no scarring or delayed-onset hypopigmentation was observed. At the 6-month follow-up visit, patient and investigator scores demonstrated improvements in skin texture for all scars (patient range, 1-4 [mean, 2.79]; investigator range, 2-4 [mean, 2.95]), pigmentation for all scars (patient range, 1-4 [mean, 2.32]; investigator range, 1-4 [mean, 2.21]), atrophy for all scars (patient range, 1-4 [mean, 2.26]; investigator range, 2-4 [mean, 2.95]), and overall scar appearance for all scars (patient range, 2-4 [mean, 2.89]; investigator range, 2-4 [mean, 3.05]). Image analysis revealed a 38.0% mean reduction of volume and 35.6% mean reduction of maximum scar depth.
The AFR treatments represent a safe, effective treatment modality for improving atrophic scarring due to surgery or trauma.
评估非剥脱性点阵激光（AFR）治疗非痤疮性萎缩性瘢痕的安全性和有效性。
在这项前后对照试验中，每个瘢痕接受3次AFR治疗，并随访6个月。
私立学术机构。
2007年6月1日至11月30日期间，15名年龄在21至66岁之间、Fitzpatrick皮肤分型为I至IV型的女性，共有22处非痤疮性萎缩性瘢痕。3名患者（3处瘢痕）在接受1次AFR治疗后未返回进行随访，被排除在研究之外。其余12名患者（19处瘢痕）完成了所有3次治疗及6个月的随访。
每个瘢痕每隔1至4个月接受3次AFR治疗。
治疗后及随访6个月期间，对红斑、水肿、瘀点、瘢痕形成、结痂和色素沉着异常进行分级。由患者和非盲法研究者在治疗后及随访6个月期间评估皮肤质地、色素沉着、萎缩及总体外观。采用三维光学轮廓分析系统生成萎缩性瘢痕的高分辨率地形图，以客观测量瘢痕体积和深度的变化。
治疗的不良反应为轻至中度，未观察到瘢痕形成或迟发性色素减退。在6个月的随访中，患者和研究者评分显示，所有瘢痕的皮肤质地（患者评分范围为1至4分[平均2.79分]；研究者评分范围为2至4分[平均2.95分]）、色素沉着（患者评分范围为1至4分[平均2.32分]；研究者评分范围为1至4分[平均2.21分]）、萎缩（患者评分范围为1至4分[平均2.26分]；研究者评分范围为2至4分[平均2.95分]）及总体瘢痕外观（患者评分范围为2至4分[平均2.89分]；研究者评分范围为2至4分[平均3.05分]）均有改善。图像分析显示，瘢痕体积平均减少38.0%，最大瘢痕深度平均减少35.6%。
AFR治疗是一种安全、有效的治疗方式，可改善手术或创伤所致的萎缩性瘢痕。
